

Dear Shareholders, Business Partners, and Friends,

The past year was not only another very good year, but we can clearly say it was a breakthrough year. Thanks to the acquisition of Fidelta and dynamic organic growth, looking at the scale of operations today, we are more than double in size compared to one year ago.

All three segments of Selvita are performing well.

During the first year of being part of Selvita, our colleagues at Fidelta have shown that they are not only well-performing in terms of profitability but can also be a dynamically growing segment of Selvita Group. Their strong specialization in selected therapeutic areas has helped us create more added value and has made Selvita Group an important partner for our client's drug discovery projects. At the beginning of 2022, we have fully integrated our services offer, which will positively impact further development of Selvita Group and help us expand our competences in additional therapeutic areas. Over two thousand square meters of additional laboratory space, they are just moving in, will enable the team in Zagreb to continue the growth in the next few years.

Teams in Krakow and Poznan also had a very good year. Both Drug Discovery and Regulatory are growing not only by doing more of the same but also thanks to the implementation of new services which make our offer more comprehensive. New technology platforms in drug discovery, like HTS with the Compound Management unit, HCS, and new capabilities based on AI solutions make Selvita more attractive as a partner for integrated drug discovery projects. Not only the above mentioned but also new activities will be intensively developed in 2022 supported by two grants, recently acquired. Regulatory services, as expected, have regained pre-pandemic dynamics, and we can observe a growing portfolio of drugs being released by our laboratories. Our ambition is to expand activities in this area and build a true drug development segment.

The most vibrant segment of the Group – Ardigen, has grown this year beyond our expectations. They have strengthened their position on the US market and have plans to continue their growth there. An essential element, the current engine of growth – digital CRO services – should soon be supported by specialized services based on their immunology, microbiome, and biomedical imaging platforms.

With a view to further organic development, we have increased the sales team in the US and West Europe by employing seasoned sales specialists and managers. The construction of our research center in Krakow is progressing according to the schedule, and we hope to start moving in at the end of 2022.

Two years ago, a few months after the split, which was finalized in October 2019, we were working on the Strategy for 2020-23. This strategy assumed continuation of the organic growth as well as entering upon the acquisition path. Both of these elements were supposed to enable us to triple the scale of operations by 2023. At that point in time, this was an unambiguously ambitious goal. Today, we see that the four-year strategy was implemented in just two years. I hope that our new plan for the next few years, which assumes continuation of the dynamic growth along



with good profitability, will be perceived as positively as the last one, and we will be proud to announce again that we have more than achieved it.

Along with the new strategy, we are opening a new chapter in cooperation with our colleagues from Zagreb, who will be fully migrated under Selvita brand starting from March 31, 2022. This will allow us to benefit from Fidelta's decades-long history of drug discovery experience. Thanks to this, we will be able to build one strong global brand.

Another good summary of how much we managed to achieve last year is also the fact that Selvita was named of the 10 best companies listed on the Warsaw Stock Exchange in 2021. We are very happy that, apart from the main ranking, we took 3rd place in the Development Prospects category, which confirms that we have good foundations and potential for further development. On behalf of Selvita, I would like to thank all our shareholders and the entire capital market for appreciating our achievements and faith in our professionalism and potential.

We can pride ourselves on all our achievements thanks to our great team of scientists and specialists. Selvita is succeeding due to the effort of the whole team, a team that, as of today, consists of over 900 people from 25 different countries. Thanks to your passion and commitment, we can continue building the global CRO organization.

I would like to thank all of our investors – your support is extremely important for us, not only during the first and second year after the split but also now when we are becoming a truly global CRO player. We are fully aware that last year's appreciation of our shares from 49.3 PLN to 82 PLN reflects not only Fidelta's acquisition and the current dynamic organic growth but also faith in further development in the coming years. As always, we will do our best to meet expectations.

With kind regards,  
Boguslaw Sieczkowski